FDA Advisory Panel Endorses GRAIL's Galleri Blood Test for Detecting More Than 50 Cancers

The US Food and Drug Administration's Molecular and Clinical Genetics Devices Panel has voted favourably on GRAIL's Galleri, a multi-cancer early detection blood test designed to identify more than 50 types of cancer through a single blood draw. The advisory committee's endorsement, delivered on September 23, is a critical step toward potential formal FDA approval of what GRAIL describes as a transformative diagnostic tool.

Galleri works by detecting cell-free DNA shed by tumours into the bloodstream and using machine learning to identify cancer-associated methylation patterns. According to GRAIL, most cancers detected by the test were found at early stages before symptoms appeared, when treatment is typically most effective. The test is designed to complement, not replace, existing cancer screening programmes for specific cancer types.

The significance lies in the breadth of detection. Current screening programmes cover only a handful of cancer types — breast, cervical, colorectal, lung and prostate account for most routine screening. More than 70 percent of cancer deaths come from types for which no recommended screening exists. A validated multi-cancer detection test could fundamentally change how oncology approaches early diagnosis.

The FDA panel's endorsement does not guarantee approval, but the agency typically follows advisory committee recommendations. If approved, Galleri would become the first multi-cancer early detection test to receive FDA clearance. The commercial and public health implications are substantial: widespread adoption could shift cancer detection toward earlier, more treatable stages across dozens of cancer types that currently lack any screening pathway.